Additional file 1: of Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines

Information on primer sequences and antibodies. Sequence information and amplicon sizes for qRT-PCR and ChIP qPCR primers as well as product information and dilution of applied antibodies are given. (PDF 271 kb

Additional file 1: Figure S1. of Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine

Viability in UCCs after sequential treatment with AZD7762 and gemcitabine. Relative cell viability in several UCCs was measured by MTT assay (mean ± SD, n = 4) after cells were sequentially treated (pretreated with AZD7762 for 24 h and then incubated with gemcitabine for 48 h). (TIF 142 kb

Additional file 2: Figure S2. of Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine

Viability in UCCs after combined treatments with cisplatin, romidepsin or givinostat, and AZD7762. a Relative cell viability in the T24 and RT-112 cell lines was measured by MTT assay (mean ± SD, n = 4) after cells were treated for 48 h either with cisplatin, romidepsin or givinostat combined with AZD7762. b Western blot analysis of S345 CHK1 after treatments with gemcitabine (10 nM), cisplatin (5 μM), romidepsin (4 nM) and givinostat (0.5 μM) in T24 cells (24 and 48 h). As loading control, GAPDH was stained. (TIF 214 kb

Additional file 3: Figure S3. of Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine

a, b Immunofluorescence staining of γH2A.X (green), 53-BP1 (red), and nuclei staining with DAPI (blue) in VM-CUB1 (a) and RT-112 (b) cells after the indicated treatments. Scale bar = 50 μm. (TIF 1728 kb

Additional file 2: of Effects of novel HDAC inhibitors on urothelial carcinoma cells

Table S1. Primers used for PCR. (DOCX 21 kb

Additional file 10: of Effects of novel HDAC inhibitors on urothelial carcinoma cells

Figure S7. Effects of treatment with 19i on primary normal urothelial cells using High Content Analysis-based fluorescent live/dead assay. Percentage of control cell counts of primary urothelial cells (culture # UP281) after 72 h treatment with TMP269 using High Content Analysis-based fluorescent live/dead assay. Data shown are mean from n = 3. (JPG 1137 kb

Additional file 1: of Effects of novel HDAC inhibitors on urothelial carcinoma cells

Figure S1. Lentiviral vector used for HDAC4 overexpression. (JPG 2487 kb

Additional file 3 of Effects of novel HDAC inhibitors on urothelial carcinoma cells

Table S2. Antibodies and conditions used for Western blotting. (DOCX 15 kb

Additional file 7: of Effects of novel HDAC inhibitors on urothelial carcinoma cells

Figure S5. Expression of HDAC1, HDAC2 and HDAC6 mRNA following treatment of UCCs with 19i or SAHA. Effects of 24 and 48 h treatment with 19i (2 μM), SAHA (2.5 μM) or DMSO as solvent control on mRNA expression of HDAC1, HDAC2 and HDAC6 in VM-CUB1, UM-UC-3 and 639-V cells. All values indicate relative expression compared to a standard for each gene, adjusted to TBP as a reference gene and set as 1 for the solvent control. Significance levels likewise refer to the solvent control (* = p < 0.05). Data shown are mean from n = 3. (PDF 105 kb